NeuroOne Medical Technologies is a thin-film electrode and radiofrequency ablation vendor whose latest quarter shows demand arriving faster than cash and controls can absorb it. Product orders outpaced recognized shipments, mix lifted product gross margin, and the exclusive Zimmer Biomet channel kept the brain franchise inside the operating room. The same quarter left a going-concern warning, a restated prior print, and a cash balance that funds operations only into early next calendar year. The investment debate is whether order conversion and mix can fund the platform before equity issuance becomes the residual claim.
The third-quarter print is a conversion story, not a demand story. Product revenue rose sixteen percent to $2 million as OneRF mix pushed product gross margin toward sixty percent. New product orders of almost $3 million left a backlog near $2 million. Fiscal-year orders already sit above eleven million, yet recognized-revenue guidance now spans a band from just over $9 million to about $11 million because contract manufacturers cannot ship as fast as Zimmer and new centers order. Margin is doing the work the top line cannot. Cash is not.
A May restatement cut the prior quarter after a customer modified a quarter-end order, and a mid-April one-for-six reverse split restored the Nasdaq bid. The at-the-market facility is already the working-capital line. The fourth quarter either converts backlog into cash or another equity draw and another control miss define the residual.